EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View

Sara Capolla iD, Maria Rasool, Giuseppe Toffoli, Michele Dal Bo

Cancer Medicine · 2025

DOI: 10.1002/cam4.70726 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Sara Capolla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO) di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico (I…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms, Hematologic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero della Salute, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell therapy based on chimeric antigen receptor (CAR) T cells has represented a revolutionary new approach for treating tumors, especially hematological diseases. Complete remission rates (CRR) > 80%–97% and 50%–90% overall response rates (ORR) have been achieved with a treatment based on CAR‐T cells in patients with malignant B‐cell tumors that have relapsed or are refractory to previous treatments. Toxicity remains the major problem. Most patients treated with CAR‐T cells develop high‐grade cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS). However, the unprecedentedly high CRR and ORR have led to the approval of six CAR‐T cell therapeutics by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), prompting researchers to improve existing products and develop new ones. By now, around 1000 clinical trials based on CAR‐T cells are registered at ClinicalTrials.gov : 82% are for hematological diseases, while the remaining 16% are for solid tumors. As a result of this increased research, an enormous amount of conflicting information has been accumulated in the literature, and each group follows its manufacturing protocols and performs specific in vitro testing. This review aimed to combine and compare clinical and preclinical information, highlighting the most used protocols to provide a comprehensive overview of the in vitro world of CAR‐T cells, from manufacturing to their characterization. The focus is on all steps of the CAR‐T cell manufacturing process, from the collection of patient or donor blood to the enrichment of T cells, their activation with anti‐CD3/CD28 beads, interleukin‐2 (IL‐2) or IL‐7 and IL‐15 (induction of a more functional memory phenotype), and their transfection (viral or non‐viral methods). Automation is crucial for ensuring a standardized final product.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenNeoplasmsHematologic NeoplasmsT-LymphocytesHumansAnimalsReceptors, Antigen, T-CellClinical Trials as TopicCytokine Release Syndrome

Stichwörter der Autor:innen

CAR‐T cellsFDA‐approved productsin vitro preclinical studiesmanufacturing process

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO) di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
  • Doctoral School in Pharmacological Sciences, University of Padua, Padova, Italy.

ORCID-Profile: Sara Capolla

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Ministero della Salute
  • European Union
  • HEAL ITALIA
  • European Commission

Zitieren

APA

Capolla, S., Rasool, M., Toffoli, G., & Dal Bo, M. (2025). CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View. Cancer Medicine. https://doi.org/10.1002/cam4.70726

Vancouver

Capolla S, Rasool M, Toffoli G, Dal Bo M. CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View. Cancer Medicine. 2025. doi:10.1002/cam4.70726

BibTeX
@article{Capolla2025,
  author = {Capolla, Sara and Rasool, Maria and Toffoli, Giuseppe and Dal Bo, Michele},
  title = {CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70726}
}
Kostenlos starten →